Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
Portfolio Pulse from Vandana Singh
Biogen Inc has agreed to acquire Reata Pharmaceuticals Inc for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata's FDA-approved Skyclarys is the first and only approved treatment for Friedreich's ataxia in the U.S. The acquisition is expected to close in Q4 2023 and is expected to be slightly dilutive to Biogen's Non-GAAP diluted EPS in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025.
July 28, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals is being acquired by Biogen for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
The acquisition is a major event for Reata and its shareholders. The agreed price per share could influence the stock's short-term price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEUTRAL IMPACT
Biogen's acquisition of Reata is expected to be slightly dilutive to its Non-GAAP diluted EPS in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025.
The acquisition is a significant move for Biogen and is expected to impact its earnings per share over the next few years. This could influence investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100